Get documents about "Letter to Shareholders Dear Fellow Shareholders_ The three month
Document Sample
Letter to Shareholders
Dear Fellow Shareholders,
The three month period ending December 31, 2006 was an eventful one for Bioniche Life Sciences. We received an
authorization from the Canadian regulator that allows us to begin distribution of our E. coli O157:H7 cattle vaccine
to Canadian veterinarians; we initiated the first of two Phase III clinical trials using Urocidin in the treatment of non
muscle-invasive bladder cancer; we liquidated further non-core assets to support our Phase III bladder cancer
program; and we paid our long-term debt down substantially.
E. coli O157:H7 Cattle Vaccine
The Canadian Food Inspection Agency (CFIA), on December 22, 2006, provided authorization for distribution of
our E. coli O157:H7 cattle vaccine to Canadian veterinarians under a Permit to Release Veterinary Biologics (the
“Permit”) as specified in the Canadian Health of Animal Regulations. Under the Permit, no marketing activities can
be conducted, but we can respond to veterinarian orders for the vaccine. In order to progress from the Permit to a
full license in Canada, we must provide additional data confirming reduction in E. coli O157:H7 shedding by
vaccinated animals. We have completed an additional efficacy study at the University of Nebraska-Lincoln and the
data is currently being analysed to determine if it meets the efficacy requirements for a full license.
We continue to pursue the registration of the vaccine in the United States. The U.S. Department of Agriculture
(USDA), after reviewing data submitted to them in August, 2005, requested an additional efficacy trial be
conducted. As noted above, this study has been completed at the University Nebraska-Lincoln according to a
protocol approved by the USDA, and we expect to submit the data to the U.S. regulator later in 2007.
The Company has commenced internal scale-up of its manufacturing capacity at its Belleville, Ontario facility,
which is expected to put the Company in a position to supply at least part of the market requirements in the early
commercialization years. The Company is also exploring different manufacturing options related to meeting full-
scale production requirements. Depending upon demand for the E. coli O157:H7 vaccine, the Company may not be
able to fully supply the market without expanding its current manufacturing capabilities. Different options will
require varying amounts of capital expenditure, for which the Company is exploring various funding options.
There are an estimated 123 million cattle in North America alone. Approximately 25 million of these North
American cattle are conditioned in feedlots, the first target market for the Company’s vaccine. The current
vaccination protocol would be for each feedlot animal to receive three doses of the vaccine. Dairy cattle are an
additional target market, of which there are approximately 15 million animals in North America, although
vaccination protocols for dairy animals have not yet been finalized. Additionally, there are an estimated 62 million
cattle in Europe.
This vaccine – a Canadian technology – has been in development since 2000. Bioniche has invested more than $13
million to develop this sophisticated technology to its current stage.
More than 30,000 cattle have been vaccinated with our vaccine over the past four years, with studies consistently
showing a decrease in the number of cattle shedding these deadly bacteria in their manure and colonizing the
bacteria in their rectal junction.
Urocidin Phase III Program
We were pleased to announce – on November 8, 2006 – that the first patient has been treated in our Phase III
clinical trial with Urocidin. In this trial, 105 non muscle-invasive bladder cancer patients who are refractory
(unresponsive) to the current standard therapy (Bacillus Calmette-Guérin - BCG) will receive Urocidin in an open
label, North American study. A number of additional patients have been enrolled since the November
announcement.
The protocol for this trial has been granted “fast track” status by the U.S. Food and Drug Administration (FDA),
meaning that the results will receive expedited review by the FDA. A total of 25 centres have committed to
participate in this refractory study. The investigators include some of the most published and well-known North
American urologists involved in treating bladder cancer.
The FDA also approved a second Phase III trial with Urocidin in the treatment of patients with non muscle-invasive
bladder cancer who have received no previous treatment. This comparative, double-blind trial will involve
approximately 700 patients in North America and Europe and is expected to begin later this calendar year. We
expect this study to demonstrate that Urocidin is superior to BCG in terms of safety and is at least as efficacious.
We continue to spend a significant amount of time in discussions with major pharmaceutical companies about a
potential marketing partnership for Urocidin. A number of companies have expressed an interest in working with
Bioniche to market this technology, and we trust that a partnership can be successfully struck at the earliest
opportunity. Ferghana Partners, an international provider of high level, independent corporate financial advice to
firms in the biotechnology, pharmaceuticals, diagnostics and specialty chemicals industries, has been retained as
agent in this partnering transaction.
Paydown of Long-Term Debt
Subsequent to the quarter end, Laurus Master Funds exercised a share conversion of US$500,000 principal payment
on the term note. This has reduced the principal amount owing on the convertible term note to US$557,432. With
this payment on January 10, 2007, the Company will have reduced its total long-term debt to $2.2 million, inclusive
of capital leases, term notes and senior debt.
Outlook for Remainder of 2007
The Company has continued to experience a challenge in its financial condition and liquidity during the first half of
Fiscal 2007. Management expects operating losses to increase in Fiscal 2007 as we continue to enroll patients in our
first Phase III trial with Urocidin for bladder cancer.
Management is currently pursuing several financing alternatives with the support of the Board of Directors. These
alternatives include completing a partnership deal to support our Phase III development program for Urocidin;
raising preferred or common equity; and finding strategic financing partners to support the animal health business.
The Company continues to pursue our value creation objectives. The clear pathway to a Canadian license for our E.
coli O157:H7 cattle vaccine was indicative of value creation, in that we saw an increase in both share price and
volume of shares traded in the days and weeks following this announcement. A full Canadian license, when issued
by CFIA, should have similar positive results.
We have not yet seen our late stage bladder cancer therapy reflected in the market capitalization of the Company.
Management believes that its value will be recognized at such time as a marketing partnership deal is consummated
with a strategic pharmaceutical partner. The terms of such a deal will provide an external valuation of this cancer
therapy for the first time.
We appreciate your continuing support as we progress toward the completion of our priority projects.
Sincerely,
Graeme McRae
President & CEO
2
MANAGEMENT’S DISCUSSION & ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS
FROM OPERATIONS
For the Period Ending December 31, 2006
The following discussion and analysis is the responsibility of management and should be read in conjunction with
the accompanying unaudited interim consolidated financial statements and associated notes as at December 31,
2006, as well as the audited consolidated financial statements and Management’s Discussion and Analysis for the
year ended June 30, 2006. The Company’s unaudited consolidated interim financial statements have been prepared
in accordance with Canadian generally accepted accounting principles (“GAAP”) for interim financial statements.
This review was performed by management with information available as at February 1, 2007.
Forward-Looking Statements
The discussion in this report contains forward-looking statements that involve risks and uncertainties, such as,
statements of the Company’s plans, objectives, expectations, and intentions. The cautionary statements made in this
report should be read as applying to all related forward looking statements wherever they appear in this report. The
Company’s future results could differ materially from those discussed here. Factors that could cause or contribute to
these differences include those discussed in “Risks and Uncertainties”. All amounts are in Canadian dollars unless
otherwise indicated.
Overview
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company that
develops, manufactures, and markets proprietary products for human and animal health markets worldwide. The
fully-integrated Company employs 185 people and has three operating business units (or segments): Human Health,
Animal Health, and Food Safety. Corporate headquarters are located in Belleville, Ontario, Canada. The Company’s
human health business unit has research and production facilities in Montréal, Québec, Canada. The animal health
business unit has product development and manufacturing facilities in Belleville, marketing and production facilities
in Athens, Georgia, USA; Pullman, Washington, USA; and Armidale, Australia; and a sales and marketing office
in Ireland.
The Company has several areas of strategic focus, including the development of effective therapies for bladder
cancer and other cancers; a cattle vaccine to help reduce E. coli O157:H7 contamination of food, water and the
environment; technologies to improve livestock reproduction; and technologies that could replace the use of
antibiotics in livestock. The Company’s existing animal health business is global in scope.
The Company has a three-fold strategy. First, it takes existing proprietary technologies and continues, through its
product development program, to enhance their proven therapeutic and prophylactic value for human and animal
use. Second, the Company works to develop these technologies to the point of commercialization, either alone or
with strategic marketing partners. Third, the Company manufactures as many products emerging from the product
development program as it can to increase profit margins, protect the integrity of its products, and enhance
shareholder value.
Highlights of the Quarter
• Total revenues reached $13.7 million after the first six months of Fiscal 2007 as compared to $12.2 million
reported in the same period last year. This increase of $1.5 million, or 12%, resulted from a strong
marketing effort by the Company’s Animal Health sales team and a better than expected response from
customers to a sales initiative launched in August.
• On November 7, 2006, the shareholders of the Company approved the adoption of a Shareholder Rights
Plan (the “Rights Plan”). The Rights Plan is designed to ensure, to the extent possible, that the Company’s
shareholders are treated fairly in connection with potential take-over bids for its common shares. The
Company believes that the Rights Plan preserves the fair treatment of shareholders, is generally consistent
with Canadian corporate practice, and addresses institutional investor guidelines.
3
• On November 8, 2006, the Company announced that the first patient was administered UrocidinTM as part
of the Phase III refractory bladder cancer trial. The study now underway uses the Company’s proprietary
Mycobacterial Cell Wall-DNA Complex (MCC – trademarked Urocidin) for the treatment of non muscle-
invasive bladder cancer in patients who are refractory (unresponsive) to Bacillus Calmette-Guérin (BCG),
a live, attenuated strain of Mycobacterium bovis and the current standard therapy. BCG therapy can result
in treatment limiting side effects in some patients.
• On December 8, 2006, the Company sold its remaining 10% ownership position in Bioniche Pharma
Holdings Limited and its right to future royalty payments related to sales of Suplasyn®, for a total of $6.7
million (US$6.0 million). As a result, the Company recorded a gain of $2.1 million on the sale of the
Suplasyn® royalty. From the proceeds, the Company partially repaid its convertible term note with Laurus
Master Funds (Laurus) in the amount of $2.6 million in cash and $0.2 million in shares for a total of $2.8
million (US $2.5 million)
• On December 22, 2006, the Company announced that it would repay an additional $1.2 million (US$1.0
million) of its debt with Laurus. The Company repaid $0.6 million on the convertible term note and $0.6
million on the revolving note. Both payments were made in shares. Further details are presented under
Liquidities and Cash Flow Statement Highlights.
• On December 22, 2006, the Company announced that it had received authorization from the Canadian
Food Inspection Agency (CFIA) to distribute its E. coli O157:H7 cattle vaccine to Canadian veterinarians
under a Permit to Release Veterinary Biologics as specified in the Canadian Health of Animal Regulations.
This authorization equates to what is referred to as a “conditional license” in the U.S.
• Subsequent to the quarter end, on January 11, 2007, the Company announced that it would repay, through
the issuance of shares, $0.6 million on the revolving note with Laurus, and that Laurus was converting $0.6
million of the convertible term note into shares. Further details are presented under Liquidities and Cash
Flow Statement Highlights.
Going Concern
The Company’s continuing losses, decreases in working capital and cash balances, and current burn rate1 have
resulted in a “going concern” uncertainty disclosure (refer to note 1). These consolidated financial statements have
been prepared in accordance with Canadian generally accepted accounting principles on a going concern basis,
which presumes that the Company will be able to realize its assets and discharge its liabilities in the normal course
of business for the foreseeable future. The Company’s committed cash obligations and expected expenditures for
the next 12 months exceed the funds available, including cash and cash equivalents.
In previous quarterly disclosures, the Company reported that it was pursuing several financing options to allow it to
execute its corporate objectives with the expectation that the current working capital would be consumed during the
fourth quarter of Fiscal 2007. The Company is performing according to its forecast. Meanwhile, the Company
continues to pursue financing alternatives including debt, preferred or common share issues, and finding strategic
partners to support its clinical programs and the animal health business. There is no assurance that these initiatives
will be completed as currently planned.
Highlights of Results of Operations
Human Health Business Unit (Bioniche Therapeutics Limited)
The Company’s human health business is operated through the business unit known as Bioniche Therapeutics
Limited. The unit develops novel and proprietary human cancer therapies. This business unit’s primary focus is on
1
Burn rate means cash flow used in operations. For more information, please refer to the section, “Non-GAAP & Other Measures” below.
4
the development of its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) for the treatment of cancers.
This unit’s clinical development and research activities are in support of these commercialization efforts.
Gross research and development expenses for the human health business unit totaled $2.4 million for the three-
month period ending December 31, 2006, as compared to $2.1 million in the same period last year. On a year-to-
date basis, the Company expended $4.8 million for gross research and development, in this unit as compared to $3.9
million recorded in the same period last year.
Government incentives for the three-month period ending December 31, 2006 totaled $0.3 million, no change from
the same period last year. On a year-to-date basis, these incentives totaled $0.7 million, as compared to $0.4 million
reported in the same period last year.
Animal Health Business Unit
The Company’s animal health business unit develops, manufactures and markets animal health biopharmaceutical
products worldwide. Established in 1979 to develop technologies to replace antibiotics and improve reproductive
performance in livestock, management believes that the Company is now the largest Canadian-owned
biopharmaceutical animal health company. The Company’s animal health products are marketed directly in Canada,
the United States, Australia and Europe, and through selected distributors in the rest of the world.
Revenues recorded in this business unit for the three-month period ending December 31, 2006 totaled $5.8 million,
as compared to $6.1 million reported in the same period last year. On a year-to-date basis, revenues were $13.2
million, as compared to $11.8 recorded in the same period last year.
Expenses other than research and development incurred by this business unit in the three-month period ending
December 31, 2006 totaled $2.0 million, representing no change from the same period last year. On a year-to-date
basis, expenses other than research and development totaled $3.8 million, as compared to $4.1 million recorded in
the same period last year.
Gross research and development expenses incurred by this business unit in the three-month period ending December
31, 2006 totaled $0.4 million, as compared to $0.7 million in the same period last year. On a year-to-date basis,
gross research and development expenses were $0.8 million, as compared to $1.4 million recorded in the same
period last year.
Food Safety Business Unit
As a result of the Company’s expertise in the animal health field, it identified an opportunity to address the issue of
animal diseases that can pose health risks to humans via food, water and environmental transmission. To pursue this
opportunity, its food safety business unit was established in July, 2001. The development and commercialization of
an E. coli O157:H7 cattle vaccine (“E. coli vaccine”) has become the lead project in this unit. Beyond the E. coli
vaccine, the food safety business unit is also researching and developing other animal vaccines that improve the
safety of food and water supplies.
The E. coli vaccine is designed to reduce the burden of the pathogenic bacterium E. coli O157:H7 in cattle and their
manure, thereby reducing contamination into the environment, groundwater and in cattle processing plants. The
vaccine has also proven to reduce the number of animals in which the bacteria can colonize (reproduce). The fewer
bacteria reproducing in the cow, the fewer bacteria will be shed in its manure. In partnership with the Vaccine and
Infectious Disease Organization (VIDO) at the University of Saskatchewan, the Company is also researching other
products in the food and water safety field.
This business unit has no revenues. It incurred gross research and development expenses of $0.8 million for the
three-month period ending December 31, 2006, as compared to $0.3 million for the same period last year. On a
year-to-date basis, the unit incurred $1.5 million in gross research and development expenses, as compared to $0.7
million reported in the same period last year.
On December 22, 2006, the Company announced that it received authorization from the Canadian Food Inspection
Agency (CFIA) to distribute the E. coli O157:H7 cattle vaccine to Canadian veterinarians. CFIA is allowing
5
distribution of the vaccine under a Permit to Release Veterinary Biologics (“the Permit”) as specified in the
Canadian Health of Animal Regulations. This equates to what is considered a “conditional license” in the United
States.
Under the Permit, no marketing activities can be conducted by the Company but it can respond to veterinarian
orders for the E. coli O157:H7 vaccine. In order to progress from the Permit to a full license in Canada, the
Company must provide additional data confirming reduction in E. coli O157:H7 shedding by vaccinated animals.
The Company has completed an additional efficacy study at the University of Nebraska-Lincoln and the data is
currently being analysed to determine whether it meets the efficacy requirements for a full license.
The Company continues to pursue the registration of the vaccine in the United States. The U.S. Department of
Agriculture (USDA), after reviewing data submitted to them in August, 2005, requested an additional efficacy trial
be conducted. As noted, this study was completed at the University Nebraska-Lincoln according to a protocol
approved by the USDA, and the Company expects to submit the data to the USDA later in calendar year 2007.
The Company has commenced internal scale-up of its manufacturing capacity at its Belleville, Ontario facility,
which is expected to put the Company in a position to supply at least part of the market requirements in the early
commercialization years. The Company is also exploring different manufacturing options for meeting full-scale
production requirements. Depending upon demand for the E. coli O157:H7 vaccine, the Company may not be able
to fully supply the market without expanding its current manufacturing capabilities. Different options will require
varying amounts of capital expenditure, for which the Company is exploring various funding options.
LAST EIGHT (8) QUARTERS CONSOLIDATED RESULTS AT A GLANCE
2007 2006 2005
$ $ $ $ $ $ $ $
(unaudited; expressed in millions of Canadian dollars) Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
Revenues 5.9 7.7 7.5 6.9 6.4 5.8 7.6 7.1
Income (loss) before research & development and other items (1.8) 0.6 (2.3) (0.4) (0.9) (0.9) - (0.7)
Loss from continuing operations (2.9) (2.7) (5.9) (3.5) (6.1) (3.7) (3.3) (3.8)
Income (loss) from discontinued operations - 7.9 9.3 0.4 0.4 0.6 0.5
Net Income (loss) (2.9) (2.7) 2.0 5.8 (5.7) (3.3) (2.7) (3.3)
Basic and fully diluted net income (loss) per share
Continuing operations (0.07) (0.07) (0.15) (0.09) (0.16) (0.11) (0.09) (0.11)
Discontinued operations 0.22 0.24 0.01 0.01 0.01 0.02
Total basic and fully diluted net income (loss) per share (0.07) (0.07) 0.07 0.15 (0.15) (0.10) (0.08) (0.09)
Results of Operations for the Three-Month Period Ending December 31, 2006
Consolidated Revenues
The Company’s revenues are now generated exclusively from product sales in its animal health business unit.
Consolidated revenues for the second quarter ending December 31, 2006 totaled $5.9 million, as compared to $6.4
million reported in the same period last year. This decrease of $0.5 million, or 8%, reflects the timing of sales for
two of the Company’s reproductive products, Folltropin®-V and Cue-Mate. As reported in the first quarter of the
fiscal year, a special marketing promotion was undertaken which resulted in increased sales during the first quarter.
The increased sales level is not expected to continue through the remainder of Fiscal 2007. Instead, management
expects that results for these products in the upcoming quarters will be more in line with the previous year’s sales.
Consolidated Cost of Goods Sold
Overall cost of goods in the animal health business unit totaled $2.7 million for the three-month period ending
December 31, 2006, as compared to $2.4 million reported in the same period last year. The overall gross profit
margin on product sales during the second quarter of fiscal 2007 decreased to 54% from 63% reported in the same
period last year. This decrease reflects inventory adjustments in one of the Company’s foreign affiliates.
6
Consolidated Expenses Other than Research and Development
Expenses other than research and development totaled $5.0 million for the three-month period ending December 31,
2006, as compared to $4.8 million recorded in the same period last year. This increase of $0.2 million, or 4%,
represents the net of:
• $0.1 million decrease in interest on long-term debt due to the refinancing and repayment of the Company’s
previous debt;
• $0.5 million decrease in foreign exchange loss as global currencies have remained somewhat stable during
this quarter as compared to the same period last year;
• $0.2 million decrease in marketing and selling expenses due to a reduction in the overall number of
products in order to focus on key branded products;
• $0.5 million increase in accreted interest on convertible term note resulting from continued redemptions of
long-term debt; and
• $0.5 million increase in amortization of deferred financing fees related to the debt repayments during the
second quarter.
Consolidated Research and Development
GROSS RESEARCH & DEVELOPMENT
(expressed in millions of Canadian dollars)
For the three and six months ended December 31 2006 2005
Q2 YTD Q2 YTD
Key Areas $ $ % $ $ %
Animal Health 0.4 0.9 13% 0.7 1.4 23%
Food Safety 0.8 1.5 21% 0.3 0.7 12%
Human Health 2.4 4.8 65% 2.1 3.9 65%
Research and Development, Gross 3.6 7.2 100% 3.1 6.0 100%
Gross research and development expenses for the three-month period ending December 31, 2006 totaled $3.6
million, as compared to $3.1 million reported in the same period last year. This increase of $0.5 million, or 16%,
reflects increased costs of $0.3 million within the human health business unit due to increased staffing in the clinical
group with the start of the Phase III clinical trial with Urocidin in the treatment of patients who are refractory to
BCG therapy, as well as third party costs associated with the Phase III clinical trial initiated in the second quarter of
Fiscal 2007. We anticipate third party costs associated with the Phase III clinical trial to increase in subsequent
quarters as the recruitment of additional patients progresses.
For the three-month period ending December 31, 2006, research and development expenditures increased by $0.5
million in the food safety business unit as compared to the same period last year. This reflects increased
expenditures associated with the ongoing field trials of the E. coli O157:H7 cattle vaccine. As a result of the
Company’s focus on the advancement of its Phase III bladder cancer program and its E. coli O157:H7 vaccine, the
Company reduced research and development expenses in the animal health business unit by $0.3 million.
Government incentives for the three-month period were stable at $0.4 million for both December 31, 2006, and the
same period in 2005.
Other Items (Consolidated)
During the three-month period ending December 31, 2006, the Company recorded a gain on the sale of its future
Suplasyn royalties of $2.1 million and a small loss on the sale of its remaining 10% ownership position in Bioniche
Pharma Holdings Limited. Cash proceeds totaled $6.7 million (US$6.0 million).
During the same three-month period last year, the Company recorded a one-time debt refinancing expense of $2.5
million related to Company’s debt restructuring.
7
Consolidated Net Income (Loss)
Net loss from continuing operations for the three months ending December 31, 2006 totaled $(2.9) million, as
compared to $(6.1) million recorded in the same period last year. The decrease in the loss of $3.2 million reflects
the gain on the sale of future Suplasyn royalties of $2.1 million recorded in the three-month period ending
December 31, 2006, and an increase in other expenses. A one-time debt refinancing fee of $2.5 million was
recorded in the three-month period ending December 31, 2005. This has not recurred in the current quarter.
Results of Operations for the Six Months Ending December 31, 2006
Consolidated Revenue
Consolidated revenues for the six months ending December 31, 2006 totaled $13.7 million, as compared to $12.2
million reported in the same period last year. This increase of $1.5 million, or 12%, primarily reflects increased
sales for two of the Company’s reproductive products, Folltropin®-V and Cue-Mate. relating to promotional efforts
during the first quarter. The increased sales level is not expected to continue through the remainder of Fiscal 2007.
Instead, management expects that results for these products in the upcoming quarters will be more in line with the
previous year’s sales.
Consolidated Cost of Goods Sold
Overall cost of goods totaled $5.9 million for the six-month period ending December 31, 2006, as compared to $4.9
million reported in the same period last year. The overall gross profit margin on sales during the six-month period
ending December 31, 2006 decreased to 57% from 60% reported in the same period last year. This decrease of 3%
reflects inventory adjustments on one of the Company’s product lines.
Consolidated Expenses
Expenses totaled $8.8 million for the six month period ending December 31, 2006, as compared to $9.0 million
recorded in the same period last year. This decrease of $0.2 million, or 2%, represents the net of:
• $0.1 million decrease in marketing and selling expenses due to a reduction in the overall number of
products in order to focus on key branded products;
• $0.5 million decrease in interest on long-term debt due to the Company’s ongoing reduction of long-term
debt;
• $0.6 million increase in accreted interest on convertible term note resulting from continued redemptions of
long-term debt;
• $0.6 million increase in amortization of deferred financing fees related to the debt repayments; and
• $0.8 million decrease in foreign exchange losses. As a result of repayments of US dollar denominated
long-term debt, the Company has fewer US dollar-dominated liabilities, but has significant US dollar-
dominated assets. The recent decline of the Canadian dollar relative to the US dollar has resulted in
foreign exchange gains this year as compared to losses recorded last year.
Consolidated Research and Development
Gross research and development expenses for the six-month period ending December 31, 2006 totaled $7.2 million,
as compared to $6.0 million reported in the same period last year. This increase of $1.2 million, or 20%, reflects
increased costs of $0.9 million within the human health business unit due to increased staffing in the clinical group
with the start of the Phase III clinical trial with Urocidin in the treatment of patients who are refractory to BCG
therapy, as well as third party costs and increased administrative support costs associated with the Phase III clinical
trial.
Research and development expenditures also increased by $0.8 million in the food safety business unit. This reflects
increased expenditures associated with the ongoing field trials of the E. coli O157:H7 cattle vaccine. As a result of
the Company’s focus on the advancement of this vaccine and its Phase III bladder cancer program, the Company
reduced research and development expenses in the animal health business unit by $0.5 million.
8
Government incentives for the six-month period ending December 31, 2006 totaled $0.8 million, as compared to
$0.5 million reported in the same period last year. Incentives recorded last year were reduced by one-time
adjustments to the Technology Partnerships Canada (TPC) claims previously submitted.
Other Items (Consolidated)
On December 8, 2006, the Company realized a gain of $2.1 million related to the sale of its future Suplasyn®
royalties and a $0.2 million loss on its remaining 10% ownership position in Bioniche Pharma Holdings Limited.
Total proceeds received were $6.7 million (US$6.0 million).
Consolidated Net Income (Loss)
Calculation of EBITDA
(expressed in millions of Canadian dollars)
2006 2005
For the three and six months ended December 31 Q2 YTD Q2 YTD
$ $ $ $
Loss before research and development and other items (1.8) (1.1) (0.9) (1.7)
Add (deduct):
Amortization 1.1 1.8 0.7 1.3
Interest 0.4 0.6 0.5 1.1
Accreted interest 0.5 0.6 - -
Foreign exchange (0.3) (0.3) 0.3 0.5
*EBITDA before research and development and other items (0.1) 1.6 0.6 1.2
*EBITDA means earnings before interest, taxes, depreciation, and amortization. For more information, please refer to the section, "Non-
GAAP & Other Measures" below.
The EBITDA before research and development and other items for the six-month period ending December 31, 2006
totaled $1.7 million as compared to $1.2 million recorded in the same period last year, a gain of $0.5 million, or
42%.
Net loss from continuing operations for the six-month period ending December 31, 2006 reached $(5.7) million or
$(0.14) per share (basic and fully diluted) compared with $(9.7) million or $(0.27) per share for the previous year.
Balance Sheet Highlights
Assets
The Company’s current assets at December 31, 2006 were $14.7 million, as compared to $16.7 million reported at
June 30, 2006. The net working capital2, excluding deferred government incentives, was $6.0 million, as compared
to $ 6.8 million reported at June 30, 2006. Long-term assets at December 31, 2006 were $19.7 million, as compared
to $24.7 million reported at June 30, 2006.
Liabilities and Shareholders’ Equity
The Company’s current liabilities at December 31, 2006 were $12.2 million, as compared to $13.4 million reported
at June 30, 2006. Long-term debt at December 31, 2006 was $2.2 million, as compared to $4.7 million reported at
June 30, 2006. Total shareholders’ equity at December 31, 2006 was $20.0 million, as compared to $23.4 million
reported at June 30, 2006.
Liquidities and Cash Flow Statement Highlights
The Company’s cash used in operations was $3.3 million during the six-month period ending December 31, 2006,
as compared to cash used in operations of $5.5 million in the same period last year. This reflects the sale of the
2
Working capital is a non-GAAP measure. For more information, please refer to “Non-GAAP & Other Measures”, below
9
Company’s 10% ownership position in Bioniche Pharma Holdings Limited and the sale of its future Suplasyn
royalties, along with increased sales and increased expenses.
The Company continues to experience challenges in its financial condition and liquidity. The Company has incurred
substantial operating losses since its inception, due primarily to its focus on research and development of
proprietary technologies. As at December 31, 2006, the Company had an accumulated deficit of $59.5 million.
Quarterly Variation Impacting the Capital Structure
During the second quarter of Fiscal 2007 and subsequently, the Company completed several significant transactions
that impacted its capital structure. These transactions are as follows:
• From October 1, 2006 to December 31, 2006, the Company issued shares in lieu of cash to repay a portion
of its revolving loan with Laurus, totaling 1,329,000 shares with a value of $858,979;
• On December 8, 2006, the Company repaid US$200,000 in principal on the term note with Laurus through
the issuance of 373,725 shares with a value of $229,804;
• On December 21, 2006, the Company repaid US$500,000 in principal on the term note with Laurus
through the issuance of 860,633 shares with a value of $574,550; and
• On January 11, 2007, the Company repaid US$500,000 in principal on the term note with Laurus through
the issue of 668,807 shares with a value of $668,121. These shares were issued at the fixed conversion
price as stipulated in the loan agreement. This represents 7% of the debt, and will result in a reduction in
the paid in capital value for the conversion option of $79,571. In addition, the Company repaid
US$500,000 in principal on the revolving note with Laurus through the issue of 409,033 shares valued at
$588,550.
These asset dispositions and debt conversions have enabled the Company to carry out its operations, including the
initiation of its Phase III clinical program in bladder cancer and the continuation of its studies to support registration
of the E. coli O157:H7 cattle vaccine while repaying $17.3 million in debt. By selling its interest in Bioniche
Pharma Group Limited, the Company also eliminated a further $33.1 million in total liabilities of that company
from its consolidated balance sheet.
Management expects operating losses to increase through Fiscal 2007 as the Company continues its Phase III trials
with Urocidin for bladder cancer under US Food and Drug Administration (FDA) approved protocols. The
Company’s committed cash obligations and expected expenditures for the next 12 months exceed the funds
available, including cash and cash equivalents.
As a result, the Company continues to pursue financing alternatives, including debt and preferred or common equity
issuances, to support present and future development activities. Further, the Company is actively seeking
collaborations to support the development of its advanced clinical program in bladder cancer and its E. coli
O157:H7 cattle vaccine, as well as finding strategic financing partners to support its animal health business. There is
no assurance that these initiatives will be completed as currently planned.
These consolidated financial statements have been prepared on a going concern basis, which presumes the Company
will continue to operate and will be able to realize its assets and discharge its liabilities and commitments in the
ordinary course of business for the foreseeable future. These consolidated financial statements do not include any
adjustments to the amounts and classifications of assets and liabilities should the Company not be able to continue
as a going concern.
The Company’s ability to continue as a going concern is dependent upon the continued support of its lenders,
suppliers, employees and customers, receiving funds through product licensing agreements or collaborative research
contracts, borrowing or equity financing, and achieving future profitable operations.
Outstanding Share Data
Common Shares
10
The Company has total common shares outstanding at February 1, 2007 of 43,568,448. In addition, the Company
has 4,470,000 outstanding warrants and 4,133,501 outstanding options, exchangeable for one common share upon
exercise. Also on February 1, 2007, the convertible term note with Laurus provides rights to exchange for an
approximate maximum of 734,570 common shares. The Series II preferred shares provide rights to exchange for a
maximum of 8,910,000 common shares.
The Company also has a commitment to issue warrants to TPC in connection with its agreements on the MCC and
E. coli O157:H7 projects. This commitment is triggered once the reimbursement exceeds 50% of the funding on
each program. During fiscal 2004 the threshold was triggered on the MCC project, and it has not yet been met on
the E. coli O157:H7 project. The parties are in ongoing negotiations to amend the agreements to substitute other
payment mechanisms for the obligation to issue warrants (see “Critical Accounting Estimates”).
Contractual Obligations
Contractual obligations have not changed significantly from the information reported in the June 30, 2006
MD&A.
Critical Accounting Estimates
The Company’s discussion and analysis of its financial condition and results of operations are based upon its
consolidated financial statements, which have been prepared in accordance with Canadian Generally Accepted
Accounting Principles (GAAP). The preparation of these financial statements requires the Company to make
estimates and judgments that affect the reported amount of assets, liabilities, revenues and expenses, and related
disclosure of contingent assets and liabilities. The Company’s critical accounting estimates are the same as reported
in the June 30, 2006 MD&A. On an ongoing basis, the Company evaluates its estimates, including cash
requirements, by assessing research and development activities and general and administrative requirements, market
need for its drug candidates, technological changes, the regulatory environment, pricing and sales expectations and
major business assumptions.
Non-GAAP & Other Measures
The following measures do not have a standardized meaning under Canadian Generally Accepted Accounting
Principles (GAAP) and, therefore, are unlikely to be comparable to similar measures presented by other companies:
• EBITDA: “Earnings Before Interest, Taxes, Depreciation, and Amortization”. The Company considers
EBITDA to be an effective measure of each business unit’s contribution to the Company on an operational
basis. It is management's view that this measure is used by analysts and shareholders to evaluate the
Company's operations.
• Burn Rate: The Company interprets this term to mean cash flow used in operations. This information can
be found in the Consolidated Statements of Cash Flows, under Operating Activities.
• Net Working Capital: current assets less current liabilities.
Risks and Uncertainties
Before making an investment decision with respect to the Company’s common shares, investors should carefully
consider the following risk factors, in addition to the other information and risks included in this report and the
annual information form and annual report for the year ending June 30, 2006. The primary risks that may affect the
Company’s business are summarized below. If any of the risks and uncertainties occurs, the business, financial
condition, prospects, and/or results of operations for the Company would likely suffer.
• Financing Requirements: The Company is dependent upon the future support of its lenders, suppliers,
employees and customers. In addition, the Company will require additional financing to continue its
operations through issuances of debt, common or preferred shares. There is uncertainty as to the
availability of additional financial resources and whether, if available, they will be provided under
acceptable conditions.
11
• Volatility of Share Prices: Company activity, including reports of new information, change in the
Company’s financial situation, the sale of shares in the market, the Company’s failure to obtain results in
line with the expectations of analysts, an announcement by the Company or any of its competitors
concerning technological innovation may cause the Company’s share price to fall.
• Dependence on Collaborative Partners, Licensors and Others: the Company’s activities will require it to
enter into various collaborative arrangements. There can be no assurance, however, that the Company will
be able to establish such collaborations on favourable terms, if at all, or that its current or future
collaborations will be successful.
• Clinical Trial Results: Clinical trials are long, expensive and uncertain processes and regulatory authorities
may ultimately not approve any of the Company’s product candidates.
• Manufacturing Facilities: the Company relies on having properly validated, fully functioning
manufacturing facilities of sufficient size in which to produce its products for market. Should systems fail,
or a disaster strike, the ability to produce products would be negatively affected which, in turn, would
affect revenue generation.
• Government Regulations: the manufacture and sale of animal and human therapeutic products is governed
by numerous statutes and regulations in the United States, Canada, Europe, and other countries where the
Company intends to market its products. There is no guarantee that the Company will be able to maintain
compliance with all regulations as changes occur.
• Key Personnel: the Company’s success is dependent upon its ability to attract and retain a highly qualified
work force, and to establish and maintain close relationships with research centres. Competition is intense
and the Company’s success will depend, to a great extent, on its senior executives, scientific staff, and
collaborators. The loss of key personnel could compromise the rhythm and success of product
development.
• Currency Risk: the Company is exposed to currency risks as a result of the export of products
manufactured in Canada and Europe, the majority of which are denominated in U.S. dollars.
• Intellectual Property must be protected to ensure the Company’s success. This will depend in part on its
ability to obtain, maintain and enforce patent rights, maintain trade secrets and operate without infringing
the proprietary rights of third parties. There is no assurance the Company’s patents will protect its
technologies.
EFFECTIVENESS OF INTERNAL CONTROLS
The President and Chief Executive Officer and the Chief Financial Officer have reviewed the effectiveness of the
Company’s disclosure and internal controls and procedures as at December 31, 2006 and have concluded that the
Company’s controls and procedures provide reasonable assurance that material information relating to the
Company, including its consolidated subsidiaries, was made known to them and reported as required, particularly
during the period in which this report was being prepared. The Company has previously identified certain areas of
required improvement relating to the Company’s internal controls. Upon discovery of these deficiencies,
management took immediate action to remediate them. The Company is also improving its formal policies with
respect to reporting of unlawful activities. On an ongoing basis, management continues to analyze its controls and
procedures for potential areas of improvement.
Recent Accounting Pronouncements
• Changes in Accounting Policies and Estimates, and Errors: In July, 2006, the Accounting Standards
Board issued a new section, “Changes in Accounting Policies and Estimates, and Errors”. This new
standard impacts when an accounting policy may be changed, how any resulting changes are to be applied,
and what disclosures must be made. Adoption is for fiscal years beginning on or after January 1, 2007. The
12
Company has not yet determined the impact of the adoption of this standard on its consolidated results of
operations or financial position. Adoption will not be required by the Company until Fiscal 2008.
• Hedges: In April, 2005, the Canadian Institute of Chartered Accountants (CICA) issued Section 3865 of
the CICA Handbook, “Hedges”, which takes effect in fiscal years beginning on or after October 1, 2006.
This section establishes standards for when and how hedge accounting may be applied. Hedging is an
activity designed to modify an entity’s exposure to one or more risks. Hedge accounting modifies the
normal basis for recognizing the gains, losses, revenues and expenses associated with a hedged item or a
hedging item in an entity’s statement of operations. It ensures that the counterbalancing gains, losses,
revenues and expenses are recognized in the same period. The Company has not determined the impact of
this standard on its consolidated results of operations or financial position. Adoption will not be required
until Fiscal 2008.
• Comprehensive Income: CICA 1530, “Comprehensive Income”, sets the standards for the reporting and
display of comprehensive income. Comprehensive income is defined as the change in equity (net assets) of
an enterprise during a period from transactions and other events and circumstances from non-owner
sources. It includes all changes in equity during a period, except those resulting from investments by
owners and distributions to owners. A statement of comprehensive income would be included in a full set
of financial statements for both interim and annual periods. The new statement would present net income
and each component to be recognized in other comprehensive income. These components would include,
for example, exchange gains and losses arising on translation of the financial statements of selfsustaining
foreign operations, which are currently included in a separate component of shareholders’ equity. This
standard is effective for fiscal years beginning on or after October 1, 2006. The Company has not
determined the impact of this standard on its consolidated results of operations or financial position.
Adoption will not be required until Fiscal 2008
• Financial Instruments – Recognition and Measurement: In January, 2005, the CICA released
Handbook Section 3855, “Financial Instruments – Recognition and Measurement”, effective for all annual
and interim periods beginning on or after October 1, 2006. All financial instruments must be classified into
prescribed categories and reclassification is rarely possible. Classification determines how each instrument
is measured and how gains and losses are recognized. The Company has not yet determined the impact of
the adoption of this standard on its consolidated results of operations or financial position. Entities are
permitted a “fresh start” in applying the new standards for classification of financial assets and liabilities.
Any adjustments to carrying amounts are recognized as adjustments to opening retained earnings or, in the
case of assets classified as available for sale or amounts previously deferred in respect of cash flow hedges
which will be redesignated as new cash flow hedges, to other comprehensive income.
Forward-Looking Statements
This discussion and analysis contains certain forward-looking statements that are subject to risks and uncertainties
that may cause the results or events predicted in this document to differ materially from actual results or events. No
assurance can be given that results, performance or achievement expressed in, or implied by, forward-looking
statements within this disclosure will occur or, if they do, that any benefit may be derived from them.
Other Information About the Company
Additional information relating to the Company, including the Annual Information Form (AIF), is available on
SEDAR at www.sedar.com.
Patrick Montpetit, CA
13
Vice-President, Finance and Chief Financial Officer
February 1, 2007
Bioniche Life Sciences Inc.
Amalgamated under the laws of Ontario
CONSOLIDATED BALANCE SHEETS
[Unaudited - see note 1]
As at December 31, As at June 30,
2006 2006
$ $
ASSETS
Current
Cash 3,625,395 4,093,293
Accounts receivable 4,673,226 5,644,956
Inventories [note 2] 5,910,458 6,171,453
Prepaid expenses and deposits 540,719 804,470
14,749,798 16,714,172
Long-term
Property, plant and equipment 9,699,803 10,138,797
Intangible assets 8,973,475 9,401,733
Goodwill 456,155 456,155
Deferred financing fees 448,978 1,258,236
Investment [note 7] — 3,298,279
Other assets 100,000 100,000
34,428,209 41,367,372
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Revolving credit facility 1,594,376 3,162,097
Accounts payable and accrued liabilities 6,095,622 5,054,593
Income and other taxes payable 598,817 494,881
Deferred government incentives 3,485,824 3,433,007
Current portion of senior debt and capital leases 427,736 1,220,840
12,202,375 13,365,418
Long-term
Senior debt 1,288,139 3,697,806
Obligations under capital lease [note 6] 901,588 953,957
14,392,102 18,017,181
Shareholders' equity
Share capital [note 3] 74,796,457 72,686,901
Other paid-in capital [note 3] 4,763,206 4,556,290
Deficit (59,523,556) (53,869,621)
Cumulative translation adjustment (23,379)
20,036,107 23,350,191
34,428,209 41,367,372
See accompanying notes
14
Bioniche Life Sciences Inc.
CONSOLIDATED STATEMENTS OF DEFICIT
[Unaudited - see note 1]
For the three and six months ended December 31
Current Last Year Current Last
Quarter Quarter Year to Date Year to Date
2006 2005 2006 2005
$ $ $ $
Deficit, beginning of period (56,610,485) (56,048,703) (53,869,621) (52,726,240)
Net loss for the period (2,913,071) (5,682,210) (5,653,935) (9,004,673)
Deficit, end of period (59,523,556) (61,730,913) (59,523,556) (61,730,913)
See accompanying notes
15
Bioniche Life Sciences Inc.
CONSOLIDATED STATEMENTS OF LOSS
[Unaudited - see note 1]
For the three and six months ended December 31
Current Last Year Current Last
Quarter Quarter Year to Date Year to Date
2006 2005 2006 2005
$ $ $ $
[Restated - [Restated -
see note 5] see note 5]
REVENUE
Sales 5,912,276 6,371,623 13,656,902 12,209,677
Cost of sales 2,745,283 2,378,380 5,936,128 4,907,684
Gross profit 3,166,993 3,993,243 7,720,774 7,301,993
EXPENSES
Administration 1,442,452 1,418,054 2,572,743 2,424,639
Marketing and selling 1,431,408 1,592,153 2,852,872 2,942,429
Quality assurance 169,539 268,992 338,046 517,896
Interest on long-term debt 299,924 365,024 494,745 999,407
Other interest 71,527 98,663 144,731 75,597
Accreted interest on convertible term note 510,587 45,562 619,413 45,562
Share ownership plan and bonus 212,661 99,944 212,661 233,115
Amortization of capital assets 295,562 309,065 590,846 611,362
Amortization of intangible assets 214,130 214,131 428,259 428,260
Amortization of deferred financing fees 634,930 176,362 809,258 244,701
Foreign exchange loss (gain) (271,665) 260,860 (283,851) 493,703
5,011,055 4,848,810 8,779,723 9,016,671
Loss before research and
development and other items (1,844,062) (855,567) (1,058,949) (1,714,678)
Research and development expenses, gross 3,561,692 3,126,982 7,151,440 5,985,334
Less: government incentives, net (413,907) (392,035) (836,534) (483,234)
Impairment of investment [note 7] — — 175,000 —
Loss on sale of investment [note 7] 17,157 — 17,157 —
Gain on sale of annual Suplasyn royalty
payments [note 7] (2,127,587) — (2,127,587) —
Debt refinancing — 2,493,920 — 2,493,920
Loss from continuing operations
before income taxes (2,881,417) (6,084,434) (5,438,425) (9,710,698)
Provision for income tax expense 31,654 6,851 215,510 35,462
Loss from continuing operations (2,913,071) (6,091,285) (5,653,935) (9,746,160)
Income from discontinued operations [note 5] — 409,075 — 741,487
Net loss for the period (2,913,071) (5,682,210) (5,653,935) (9,004,673)
Basic and diluted net income (loss) per share
Continuing operations (0.07) (0.16) (0.14) (0.27)
Discontinued operations — 0.01 — 0.02
Basic and diluted net loss per share (0.07) (0.15) (0.14) (0.25)
See accompanying notes
16
Bioniche Life Sciences Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
[Unaudited - see note 1]
For the three and six months ended December 31
Current Last Year Current Last
Quarter Quarter Year to Date Year to Date
2006 2005 2006 2005
$ $ $ $
[Restated – [Restated –
see note 5] see note 5]
OPERATING ACTIVITIES
Loss from continuing operations (2,913,071) (6,091,285) (5,653,935) (9,746,160)
Add (deduct) non cash items:
Amortization 1,144,622 699,558 1,828,363 1,284,323
Accreted interest on convertible term note 510,587 45,562 619,413 45,562
Foreign exchange gain 351,777 129,936 345,644 103,121
Stock based compensation 55,242 37,534 111,022 110,709
Share compensation 81,000 90,002 81,000 90,002
Employee share ownership plan 212,662 141,840 212,662 278,194
Impairment of investment 175,000
Loss on investment 17,157 17,157
Gain on sale of future Suplasyn royalty
payments (2,127,587) (2,127,587)
Debt refinancing 1,271,454 1,271,454
(2,667,611) (3,675,399) (4,391,261) (6,562,795)
Net change in non-cash working capital balances 792,819 329,453 1,097,708 1,024,208
Cash used in operating activities (1,874,792) (3,345,946) (3,293,553) (5,538,587)
INVESTING ACTIVITIES
Payment relating to acquisition of net assets (123,120)
Proceeds from sale of investment 3,196,200 3,196,200
Proceeds from sale of annual Suplasyn royalty
Payments 3,652,800 3,652,800
Government incentives received
on account of capital assets 30,224 53,730 30,224 53,730
Purchase of capital assets (74,671) (193,569) (182,076) (316,913)
Cash provided by (used in) investing activities 6,804,553 (139,839) 6,697,148 (386,303)
FINANCING ACTIVITIES
Proceeds from revolving credit facility 4,051,250 4,051,250
Proceeds from term bridge loan 8,681,250 8,681,250
Common shares issued 1,053,693 1,053,693
Proceeds from convertible term note 7,048,807 7,048,807
Financing fees – debt (1,368,789) (1,368,789)
Proceeds on account of deferred
government incentives 74,282 693,861 74,282 693,861
Proceeds (repayment) of revolving credit facility 12,113 (653,367)
Repayment of senior and other long-term debt (2,982,467) (16,038,627) (3,292,408) (16,246,731)
Cash provided by (used in) financing activities (2,896,072) 4,121,445 (3,871,493) 3,913,341
Net increase (decrease) in cash from continuing operations 2,033,689 635,660 (467,898) (2,011,549)
Net increase in cash from discontinued operations 344,318 779,762
Net increase (decrease) in cash for the period 2,033,689 979,978 (467,898) (1,231,787)
Cash, beginning of period 1,591,706 1,315,643 4,093,293 3,527,408
Cash, end of period 3,625,395 2,295,621 3,625,395 2,295,621
See accompanying notes
17
Bioniche Life Sciences Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2006 and 2005 - Unaudited
1. NATURE OF THE BUSINESS, BASIS OF PRESENTATION AND GOING
CONCERN UNCERTAINTY
Bioniche Life Sciences Inc., [“the Company”], is a Canadian biopharmaceutical company engaged in the research,
development, manufacturing and commercializing of human and animal health products and technologies
worldwide. The Company's consolidated financial statements have been prepared in accordance with Canadian
generally accepted accounting principles. The Company’s common stock is traded on the Toronto Stock Exchange
[“TSX” symbol “BNC]”.
These interim financial statements do not contain all disclosures required by Canadian generally accepted
accounting principles for annual financial statements and, accordingly, these financial statements should be read in
conjunction with the most recently prepared annual financial statements for the year ended June 30, 2006. These
unaudited interim consolidated financial statements follow the same accounting policies and methods of their
application as outlined in the most recent annual consolidated financial statements.
The preparation of the consolidated financial statements requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities at the date
of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting
periods. The reported amounts and note disclosures are determined using management’s best estimates based on
assumptions that reflect the most probable set of economic conditions and planned courses of action. Actual results,
however, may differ from the estimates used in these consolidated financial statements and such differences may be
material.
At December 31, 2006, the Company had incurred significant losses and had an accumulated deficit of $59,523,556.
The Company’s committed cash obligations and expected level of expenses for the next twelve months exceeds the
cash on hand. To date, the Company has financed its cash requirements primarily through issuances of shares and
debt, investment tax credits, sale of products, royalties, government grants, and a revolving credit facility. The
Company continues to pursue an alliance with a strategic partner to fund the development program for Urocidin,
and other financing initiatives including long-term debt financing and further equity issues The Company’s ability
to continue as a going concern is dependent on the successful conclusion of either of the above initiatives in the near
term and its ability to continue to sell its products at positive margins, to bring new products to market, obtain
regulatory approvals, achieve future profitable operations, to enter into other research collaborations and to obtain
additional financing. The outcome of these matters is dependent upon factors outside of the Company’s control. As
a result, there is significant uncertainty as to whether the Company will have the ability to continue as a going
concern.
These consolidated financial statements have been prepared in accordance with Canadian generally accepted
accounting principles on a going concern basis, which presumes the Company will continue in operations for the
foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary
course of business for the foreseeable future. These consolidated financial statements do not include any
adjustments to the amounts and classifications of assets and liabilities should the Company not be able to continue
as a going concern.
18
Bioniche Life Sciences Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2006 and 2005 - Unaudited
2. INVENTORIES
December 31, 2006 June 30, 2006
$ $
Raw materials 1,053,778 1,153,542
Work in process 1,866,220 2,225,261
Finished goods 2,990,460 2,792,650
5,910,458 6,171,453
3. SHARE CAPITAL AND OTHER PAID-IN CAPITAL
Issued share capital consists of the following:
December 31, 2006 June 30, 2006
$ $
Preferred shares – Series I – 167 161,000 161,000
Preferred shares – Series II – 12,000,000 11,731,716 11,731,716
Common shares – 42,450,857 [June 30, 2006 – 39,198,140] 62,903,741 60,794,185
74,796,457 72,686,901
The change in issued and fully paid common shares of the Company during the six months ended December 31,
2006 are as follows:
December 31, 2006
Shares Amount
# $
Opening balance 39,198,140 60,794,185
Issued as a result of:
Employee share ownership plan [i] 307,385 209,791
Share compensation [ii] 115,262 81,000
Term debt repayment in shares [iii] 1,234,358 804,352
Principal repayments of revolving debt [iv] 1,595,712 1,014,413
Ending balance 42,450,857 62,903,741
[i] Employee share ownership plan
Following the approval of shareholders at the annual general meeting, shares available under this plan were
increased to 4 million. The Company issued 253,053 shares in the second quarter [307,385 shares year to
date] to bring the plan up to date, valued at $253,953 of which $44,162 remains to be issued and $41,291
relates to the accrued balance at June 30, 2006 which was included in Other paid-in capital.
19
Bioniche Life Sciences Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2006 and 2005 - Unaudited
[ii] Share compensation
During the quarter ended December 31, 2006, the Company issued 5,264 shares valued at $4,001 [2006 –
Nil] under the terms of employment agreements with sales representatives and 109,998 shares valued at
$76,999 [2006 - $90,002] to directors in lieu of directors fees. The outstanding balance in Other paid-in
capital represents the value of previous year bonuses for which the shares have not yet been issued.
[iii] Term debt repayment in shares
During the quarter ended December 31, 2006, senior long-term debt principal of $700,000 US was converted
to 1,234,358 shares valued at $804,352.
[iv] Revolving debt principal payments made in shares
During the quarter ended December 31, 2006, the Company issued 1,329,000 common shares [1,595,712
year to date] to Laurus Master Funds, Ltd. in lieu of cash principal repayments of revolving debt, valued at
$858,979 [$1,014,413 year to date].
The weighted average common shares outstanding at December 31, 2006 were 39,759,475 [June 30, 2006 –
36,396,501]
Stock option plan
No options have been granted to date this year. During the quarter ended December 31, 2006, 25,000 options with
an exercise price of $2.80 expired. The fair value of options previously granted is expensed over the vesting period
of the options. The amount recognized as a compensation expense for the year to date was $111,022 [2006 -
$110,709].
Warrants
During the quarter ended December 31, 2006, five-year warrants to purchase 200,000 shares at $1.00 were granted
to Laurus Master Funds, Ltd. as described in note 7. The value determined using the Black-Scholes pricing model
assuming risk-free interest rate of 5.2%, expected dividend yield of 0%, expected volatility of 45% and expected
warrant life of five years, was $93,023.
The Company also has a commitment to issue warrants to TPC in connection with its agreements on the MCC and
E.coli O157:H7 projects. This commitment is triggered once the reimbursement exceeds 50% of the funding on
each program. During fiscal 2004 the threshold was triggered on the MCC project, but has not yet been met on the
E.coli O157:H7 project. The parties are in ongoing negotiations to amend the agreements to substitute other
payment mechanisms for the obligation to issue warrants.
20
Bioniche Life Sciences Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2006 and 2005 - Unaudited
Other paid-in capital
Other paid-in capital consists of the following:
December 31, 2006 June 30, 2006
$ $
Employee share ownership plan [i above] 44,162 41,291
Stock options 549,670 438,648
Share compensation [ii above] 19,889 19,889
Conversion option on convertible term note 1,028,900 1,028,900
Warrants 1,920,585 1,827,562
Accrued warrants 1,200,000 1,200,000
4,763,206 4,556,290
4. SEGMENTED FINANCIAL INFORMATION
The Company’s three reportable segments or business units, Animal Health, Human Health and Food Safety, that
offer different products and require different technology and marketing strategies.
In its June 30, 2006 financial statements, the Company changed the composition of its reportable segments to
include a segment for corporate costs. The comparative segmented information for the quarter and six-month
period ended December 31, 2005 have been reclassified to reflect this change. These same periods have also been
restated to reflect the sale of Cystistat as a discontinued operation. [see note 5[b]].
The Company accounts for inter-segment sales on a cost plus basis.
Current Quarter December 2006
Human Animal Food
Health Health Safety Corporate Total
$ $ $ $ $
Sales 141,488 5,770,788 — — 5,912,276
Cost of sales — 2,745,283 — — 2,745,283
Expenses 845 1,955,808 — 1,299,407 3,256,060
EBITDA before research and
development and other items 140,643 1,069,697 — (1,299,407) (89,067)
Research & development
expenses, gross 2,353,888 394,559 813,245 — 3,561,692
Less: government incentives, net (293,808) — (120,099) — (413,907)
Net research and development
expenses 2,060,080 394,559 693,146 — 3,147,785
Interest expense, net — 22,285 — 859,753 882,038
Amortization of capital assets
and intangible assets 271,579 200,839 16,585 20,689 509,692
Amortization of deferred
financing fees — — — 634,930 634,930
Impairment/loss on investment — — — 17,157 17,157
Gain on sale of annual Suplasyn (2,127,587) (2,127,587)
royalty payments
Foreign exchange gain — — — (271,665) (271,665)
Segment income (loss) before
income taxes (2,191,016) 452,014 (709,731) (432,684) (2,881,417)
Inter-segment sales — — — 3,425,573 3,425,573
21
Bioniche Life Sciences Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2006 and 2005 - Unaudited
Last Year Quarter December 2005 [Restated]
Human Animal Food
Health Health Safety Corporate Total
$ $ $ $ $
Sales 235,640 6,135,983 — — 6,371,623
Cost of sales — 2,378,380 — — 2,378,380
Expenses 78,077 2,029,425 — 1,271,641 3,379,143
EBITDA before research and
development and other items 157,563 1,728,178 — (1,271,641) 614,100
Research & development
expenses, gross 2,110,885 692,572 323,525 — 3,126,982
Less: government incentives, net (341,344) — (50,691) — (392,035)
Net research and development
expenses 1,769,541 692,572 272,834 — 2,734,947
Interest expense, net — 22,886 — 486,363 509,249
Amortization of capital assets
and intangible assets 279,938 212,319 13,588 17,351 523,196
Amortization of deferred
financing fees — — — 176,362 176,362
Debt refinancing — — — 2,493,920 2,493,920
Foreign exchange loss — — — 260,860 260,860
Segment income (loss) before
income taxes (1,891,916) 800,401 (286,422) (4,706,497) (6,084,434)
Inter-segment sales — — — 3,262,984 3,262,984
Current Year to Date December 2006
Human Animal Food
Health Health Safety Corporate Total
$ $ $ $ $
Sales 490,719 13,166,183 — — 13,656,902
Cost of sales — 5,936,128 — — 5,936,128
Expenses 12,406 3,801,858 — 2,162,058 5,976,322
EBITDA before research and
development and other items 478,313 3,428,197 — (2,162,058) 1,744,452
Research & development
expenses, gross 4,799,345 837,545 1,514,550 — 7,151,440
Less: government incentives, net (673,291) — (163,243) — (836,534)
Net research and development
expenses 4,126,054 837,545 1,351,307 — 6,314,906
Interest expense, net — 41,364 — 1,217,525 1,258,889
Amortization of capital assets
and intangible assets 542,833 401,566 33,611 41,095 1,019,105
Amortization of deferred
financing fees — — — 809,258 809,258
Impairment/loss on investment — — — 192,157 192,157
Gain on sale of annual Suplasyn (2,127,587) (2,127,587)
royalty payments
Foreign exchange gain — — — (283,851) (283,851)
Segment income (loss) before
income taxes (4,190,574) 2,147,722 (1,384,918) (2,010,655) (5,438,425)
Inter-segment sales — — — 7,308,142 7,308,142
22
Bioniche Life Sciences Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2006 and 2005 - Unaudited
Last Year to Date December 2005 [Restated]
Human Animal Food
Health Health Safety Corporate Total
$ $ $ $ $
Sales 445,551 11,764,126 — — 12,209,677
Cost of sales — 4,907,684 — — 4,907,684
Expenses 160,437 4,056,076 — 1,901,566 6,118,079
EBITDA before research and
development and other items 285,114 2,800,366 — (1,901,566) 1,183,914
Research & development
expenses, gross 3,919,448 1,354,819 711,067 — 5,985,334
Less: government incentives, net (358,524) — (124,710) — (483,234)
Net research and development
expenses 3,560,924 1,354,819 586,357 — 5,502,100
Interest expense, net — 47,582 — 1,072,984 1,120,566
Amortization of capital assets
and intangible assets 559,851 430,190 13,961 35,620 1,039,622
Amortization of deferred
financing fees — — — 244,701 244,701
Debt refinancing — — — 2,493,920 2,493,920
Foreign exchange loss — — — 493,703 493,703
Segment income (loss) before
income taxes (3,835,661) 967,775 (600,318) (6,242,494) (9,710,698)
Inter-segment sales — — — 5,933,059 5,933,059
5. DISCONTINUED OPERATIONS
[a] Sale of Bioniche Pharma Group
The Company’s Board of Directors resolved in May 2005 to dispose of the Bioniche Pharma segment of its
business comprised of manufacturing operations in Galway, Ireland and sales operations in Canada and the United
States. Accordingly, all revenues, expenses, assets and liabilities related to the Pharma segment were classified as
discontinued operations for 2005.
Income from discontinued operations
Last Year Last
Quarter Year to Date
2005 2005
$ $
Revenues 5,389,537 10,886,587
Cost of sales 2,320,633 4,347,430
Gross profit 3,068,904 6,539,157
Expenses 2,881,657 5,043,088
187,247 1,496,069
Net research and development expenses (350,731) (717,248)
Interest, amortization and income taxes 70,246 (596,069)
Non-controlling interest (6,963) (33,943)
Operating income (loss) (100,201) 148,809
23
Bioniche Life Sciences Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2006 and 2005 - Unaudited
[b] Sale of Cystistat®
On May 23, 2006, the Company closed the sale of its proprietary sodium hyaluronate product, Cystistat®, to
Bioniche Teoranta of County Galway, Ireland, for $10,000,000. Bioniche Teoranta is part of the New Bioniche
Pharma sold by Bioniche Life Sciences to RoundTable Healthcare Partners as outlined above. Accordingly, 2005
has been restated to classify of all revenues, expenses, assets and liabilities related to Cystistat as a discontinued
operations.
Income from discontinued operations
Last Year Last
Quarter Year to Date
2005 2005
$ $
[Restated] [Restated]
Revenues 1,050,426 1,526,346
Cost of sales 353,976 503,803
Gross profit 696,450 1,022,543
Expenses 143,761 255,643
552,689 766,900
Net research and development expenses (43,413) (174,222)
Operating income 509,276 592,678
Consolidated cash flow provided by (used in) discontinued operations:
Last Year Last
Quarter Year to Date
2005 2005
$ $
[Restated] [Restated]
Operating activities 2,345,131 4,176,980
Investing activities (1,435,424) (2,100,435)
Financing activities (410,331) (837,334)
Effect of foreign currency translation (155,058) (459,449)
Net increase in cash from discontinued operations 344,318 779,762
6. RELATED PARTY TRANSACTIONS
During the first two quarters of fiscal 2007 and 2006, the Company made monthly lease payments of $16,667 per
month to a company controlled by the CEO who is also a Director of the Company.
24
Bioniche Life Sciences Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2006 and 2005 - Unaudited
7. IMPAIRMENT AND LOSS ON SALE OF INVESTMENT AND GAIN ON SALE
OF ANNUAL SUPLASYN ROYALTY PAYMENTS
On December 6, 2006, the Company sold its 10% investment in Bioniche Pharma Holdings Limited (Pharma) for
US $2.8 million [$3,196,200]. The Company has retained its right to the earnout in Pharma. No amounts in respect
of the earnout have been recorded in the financial statements. The carrying amount of the investment had been
previously reduced by a $175,000 impairment charge to $3,123,279 in the quarter ended September 30, 2006 to
reflect the estimated selling price at that time. The net loss of $17,157 in the current quarter includes selling costs,
which include the fair value of warrants of $43,411 issued to the senior debt holder to release its collateral and other
fees of $46,667.
This sale also included the sale of the Company’s right to future Suplasyn royalty payments for US $3.2 million
[$3,652,800]. The gain of $2,127,587 recorded as a result of this sale is net of previously accrued royalties of
$1,422,268 of which $490,719 had been recorded during the six-month period ended December 31, 2006. Selling
costs, which include the fair value of warrants of $49,612 issued to the senior debt holder to release its collateral
and other fees of $53,333, amount to $102,945.
Upon closing, US $2.3 million [$2,667,770] of the proceeds were used to repay senior debt. In addition, 200,000
five-year warrants valued at $93,023, were issued to the senior debt holder and have been allocated as noted above.
As a result of the pre-payment of the Laurus term note, the Company has amortized the related debt discount,
deferred financing fees as well as recognizing the imputed interest on the convertible term note related to the equity
portion of the debt and accrued withholding tax on the debt discount.
8. COMPARATIVE CONSOLIDATED FINANCIAL STATEMENTS
The comparative consolidated financial statements have been reclassified from statements previously presented to
conform to the presentation of the 2006 consolidated financial statements.
9. SUBSEQUENT EVENTS
On January 10, 2007, the Company issued 409,033 shares valued at $588,550 [US $500,000] as principal payment
on the revolving credit facility, issued at the volume weighted average price for the 10 trading days up to the date of
issuance. On the same day, Laurus Master Funds, Ltd. exercised their conversion option for US $500,000 principal
on the term note, at the contract fixed conversion price, receiving 668,807 shares valued at $588,550. This
represents 7.14% of the debt, and will result in an allocation of the paid-in capital value of the conversion option of
$79,571 to common shares.
As a result of the term note conversion, the outstanding balance of the note at January 10, 2007 is US $557,432.
25
